BIOLOGICAL · Unmapped registry intervention
HER2Bi-armed activated T cells
Find medicine records ·
Find other trials using this name
Clinical trial
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
NCT01022138
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Cyclophosphamide
Normalized identity: cyclophosphamideView linked drug · Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
Laboratory biomarker analysis
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedLaboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
HER2Bi-armed activated T cellsBIOLOGICAL
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
Sponsors & collaborators
Barbara Ann Karmanos Cancer Institutelead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01022138 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.